Ozempic Pancreatitis Risk: Real Evidence Reviewed

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

GLP-1 agonists, including semaglutide and liraglutide, showed a 9.09 times higher adjusted risk for pancreatitis compared to bupropion-naltrexone in one study [https://jamanetwork.com/journals/jama/fullarticle/2810542].
A study of 16 million patients from 2006-2020 found 4.6 (2) cases of pancreatitis among semaglutide users and 7.9 (71) among liraglutide users [https://jamanetwork.com/journals/jama/fullarticle/2810542].
GLP-1 medications can cause gastroparesis, or stomach paralysis, by slowing down the digestive tract [https://www.nationaljewish.org/specialties/gastroenterology/what-patients-should-know-about-glp-1s-and-gastroparesis].
The BMJ has issued a new warning about GLP-1 drugs following a rise in reported deaths from pancreatitis [https://www.bmj.com/content/392/bmj.s204].

GLP-1 medications, like Ozempic and Wegovy, have become popular tools for managing type 2 diabetes and supporting weight loss. While these drugs can offer significant benefits, including an average weight loss of 30 to 40 pounds over a few months for some patients, real data shows they also carry risks of serious gastrointestinal side effects. One significant concern is pancreatitis. A large-scale cohort study revealed that GLP-1 agonists had an adjusted hazard ratio of 9.09 (95% CI, 1.25-66.00) for pancreatitis when compared to bupropion-naltrexone users [https://jamanetwork.com/journals/jama/fullarticle/2810542]. This means users of GLP-1s showed a substantially elevated risk for this severe inflammation of the pancreas. Beyond pancreatitis, other serious issues like gastroparesis, biliary disease, and bowel obstruction have also been linked to these medications. It is crucial for patients and healthcare providers to understand these risks based on solid evidence.

What are GLP-1 Medications?

GLP-1 medications are a class of drugs that were originally developed to treat type 2 diabetes. These powerful medications mimic the action of a natural hormone in the body called glucagon-like peptide-1. This hormone helps regulate blood sugar by increasing insulin release when blood sugar levels are high, decreasing glucagon secretion, and slowing down how fast food moves through the stomach. This last effect, slowing gastric emptying, is key to both their benefits and some of their side effects.

From Diabetes to Weight Loss

Over the past few years, GLP-1 medications have gained national attention. While they first served as a cornerstone for managing type 2 diabetes, their effectiveness in promoting weight loss quickly became clear. Drugs such as Ozempic and Wegovy, which contain semaglutide, are now widely prescribed for weight management, often with dramatic results. Cardiologist Andrew Freeman, MD, reported on the significant impact these drugs have had on his patients, stating, "Some of my patients have lost about 30 to 40 pounds over the course of two or three months." This new option has been welcomed in the ongoing fight against obesity.

How GLP-1s Work for Weight Loss

The mechanism behind GLP-1s' weight loss effects involves several pathways. By stimulating insulin release and suppressing glucagon, they help control blood sugar, which can reduce cravings and improve metabolic health. The most relevant mechanism for weight loss, however, is the slowing of gastric emptying. This means food stays in the stomach for a longer period, leading to a prolonged feeling of fullness, or "early satiety." This sense of fullness helps people eat less, which in turn leads to weight loss. This effect on the digestive tract is also directly related to some of the gastrointestinal side effects observed with these medications. As prescriptions for GLP-1s have increased, so have questions and concerns about potential side effects, including serious digestive issues. Understanding these mechanisms and risks is vital for anyone considering or currently using these medications. The promise of significant weight loss must be weighed against the potential for severe adverse events.

The Rise of GLP-1s and Associated Questions

The introduction of GLP-1 medications for weight loss has marked a significant shift in obesity treatment. For many, these drugs offer a new hope in managing a condition that has long been resistant to conventional approaches. The dramatic results reported by patients and healthcare providers alike highlight their efficacy. However, the rapid increase in prescriptions has also brought a sharper focus on their safety profile. As more people use these medications, the incidence of less common but serious side effects becomes more apparent. This necessitates a thorough examination of the available evidence to ensure that patients are fully informed about both the benefits and the potential risks. The scientific community continues to gather and analyze data to provide a comprehensive picture of GLP-1 agonists' long-term effects. Our ongoing analysis of real-world data helps us provide a clear picture of what patients can expect.

Is Pancreatitis a Real Risk with GLP-1s?

Yes, pancreatitis is a real and significant risk associated with GLP-1 medications. Recent large-scale research provides clear evidence of this increased risk, prompting warnings for healthcare professionals and patients alike. This severe inflammation of the pancreas can be a life-threatening condition, and its connection to GLP-1 agonists warrants careful attention.

Evidence from a Large Cohort Study

A comprehensive cohort study investigated the risks of gastrointestinal adverse events linked to GLP-1 receptor agonists when used for weight loss. This study utilized a random sample of 16 million patients from the PharMetrics Plus for Academics database, covering the years 2006 to 2020 [https://jamanetwork.com/journals/jama/fullarticle/2810542]. This extensive health claims database captures a vast majority (93%) of all outpatient prescriptions and physician diagnoses in the US, using International Classification of Diseases (ICD-9) or ICD-10 codes. The researchers focused on new users of semaglutide or liraglutide, the two main GLP-1 agonists, and compared their outcomes to new users of bupropion-naltrexone, an active comparator weight loss agent that is not related to GLP-1 agonists. To ensure the study focused on weight loss indications, all GLP-1 agonist and bupropion-naltrexone users had an obesity code in the 90 days prior or up to 30 days after cohort entry, and those with a diabetes or antidiabetic drug code were excluded.

The Elevated Risk of Pancreatitis

The findings from this study are stark. In the primary analysis, GLP-1 agonists demonstrated a significantly elevated adjusted hazard ratio (HR) of 9.09 (95% CI, 1.25-66.00) for pancreatitis compared to bupropion-naltrexone users [https://jamanetwork.com/journals/jama/fullarticle/2810542]. This means that individuals taking GLP-1 agonists for weight loss were more than nine times as likely to develop pancreatitis than those taking bupropion-naltrexone. When we look at the raw numbers, the incidence of pancreatitis among semaglutide users was 4.6 (2 cases), while among liraglutide users, it was 7.9 (71 cases). In comparison, bupropion-naltrexone users had a much lower incidence of 1.0 (1 case) of pancreatitis. The median follow-up period for semaglutide users in this study was 0.6 years (0.2-1.1 IQR), for liraglutide users it was 1.7 years (0.8-3.1 IQR), and for bupropion-naltrexone users it was 1.7 years (0.7-2.9 IQR). These follow-up durations allowed for sufficient time to observe adverse events.

Sensitivity Analyses and Consistent Findings

The researchers also conducted sensitivity analyses to ensure the robustness of their findings. Even after excluding patients with hyperlipidemia, which can be a risk factor for pancreatitis, the adjusted hazard ratio for pancreatitis among GLP-1 agonist users remained high at 7.99 (95% CI, 1.10-58.30). Furthermore, an analysis using a less-restrictive obesity definition still showed a significant adjusted HR of 5.94 (95% CI, 1.90-18.60) for pancreatitis. These consistent results across different analytical approaches reinforce the conclusion that GLP-1 agonists are associated with a substantially increased risk of pancreatitis. The E-value for the adjusted HR for pancreatitis was 17.67, indicating a strong association that would require a powerful unmeasured confounder to explain away the observed effect. For more details, see Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight.

Warnings from Medical Authorities

The medical community has taken note of these risks. The BMJ, a leading medical journal, has reported a new warning about GLP-1 drugs following a rise in reported deaths from pancreatitis [https://www.bmj.com/content/392/bmj.s204]. This serious alert underscores the importance of careful patient selection, thorough monitoring, and clear communication of risks by healthcare providers. Patients considering or currently using GLP-1 medications for weight loss must be aware of the potential for pancreatitis and seek immediate medical attention if they experience symptoms such as severe abdominal pain, nausea, vomiting, or fever. The evidence clearly indicates that this is not a rare or negligible concern but a serious adverse event that requires vigilance.

How Do GLP-1s Affect the Digestive System?

GLP-1 medications profoundly affect the digestive system, primarily by slowing down the movement of food through the gastrointestinal tract. This mechanism is central to their effectiveness in blood sugar control and weight loss but also accounts for many of their associated side effects, including the risk of pancreatitis and other serious gastrointestinal issues.

The Mechanism of Action: Slowed Gastric Emptying

The core way GLP-1s impact digestion is by delaying gastric emptying. This means that food remains in the stomach for a longer period before moving into the small intestine. This delayed transit contributes to the feeling of fullness, or "early satiety," that helps patients eat less and lose weight. It also helps to prevent rapid spikes in blood sugar after meals, which is beneficial for individuals with type 2 diabetes. However, this intentional slowing of the digestive process can also lead to a cascade of other effects throughout the gut. The balance between therapeutic benefit and potential disruption to normal digestive function is a critical aspect of GLP-1 therapy.

Impact on Gut Motility and Beyond

While the slowed gastric emptying is a desired effect, in some individuals, this slowing can become excessive, leading to significant discomfort and more severe conditions. Gastroenterologist Pranav Periyalwar, MD, explained the impact of GLP-1s on the digestive tract, noting, "In some cases, this slowing down of the process causes both diarrhea and constipation. So, we really want to alert people on GLP-1s about this possibility." This highlights how the same mechanism can manifest in different ways, leading to a range of gastrointestinal symptoms. The gut's complex network of nerves and muscles, responsible for peristalsis (the wave-like contractions that move food), can be significantly altered by GLP-1s. This alteration can sometimes lead to a disruption of the normal rhythm and function of the digestive system, resulting in various symptoms from mild discomfort to severe complications.

Broader Gastrointestinal System Effects

The influence of GLP-1s extends beyond just the stomach. The entire digestive tract is a complex, interconnected system, and changes in one part can affect others. For instance, the slowing of gastric emptying can influence nutrient absorption rates, alter gut microbiome composition, and potentially impact the function of other digestive organs like the pancreas and gallbladder. The study on gastrointestinal adverse events with GLP-1 agonists revealed increased risks not only for pancreatitis but also for biliary disease, bowel obstruction, and gastroparesis [https://jamanetwork.com/journals/jama/fullarticle/2810542]. These conditions underscore the widespread impact these medications can have on the digestive system. Understanding these effects is crucial for managing patient expectations and for clinicians to monitor for potential complications. The comprehensive view of how GLP-1s interact with the digestive system is continuously evolving as more real-world data becomes available.

Balancing Benefits with Digestive Health

The therapeutic benefits of GLP-1 medications for weight loss and diabetes management are undeniable. However, these benefits come with a need to carefully manage the potential for digestive side effects. The intentional slowing of digestion is a double-edged sword: it helps with satiety and blood sugar control, but it also introduces risks of significant gastrointestinal distress and serious conditions. Patients must be educated on these possibilities, and healthcare providers must be vigilant in monitoring for symptoms. Open communication about digestive changes is key to identifying and addressing potential complications early, ensuring that the overall health and well-being of the patient remain the top priority.

What is Gastroparesis and Its Link to GLP-1s?

Gastroparesis, often referred to as stomach paralysis, is a medical condition characterized by a significant delay in the emptying of the stomach's contents into the small intestine. This delay is not due to a blockage but rather to problems with the nerves and muscles that control the stomach's contractions. Recent evidence clearly links GLP-1 medications to an increased risk of developing this condition.

Understanding Gastroparesis

Gastroenterologist Pranav Periyalwar, MD, explained, "Gastroparesis is essentially a delay in the emptying of the stomach." This delay can cause a range of symptoms, including nausea, vomiting, bloating, early satiety (feeling full after eating only a small amount of food), abdominal pain, and sometimes even weight loss or malnutrition due to difficulty eating. The causes of gastroparesis can vary. Dr. Periyalwar noted, "Sometimes it's caused from diabetes and years of desensitizing the nerve endings in the gut, which can decrease the motility of the stomach. Sometimes it can be idiopathic, meaning there's no clear cause. And sometimes, it’s caused by a GLP-1" [https://www.nationaljewish.org/specialties/gastroenterology/what-patients-should-know-about-glp-1s-and-gastroparesis]. This direct acknowledgment of GLP-1s as a cause highlights a critical concern for users of these medications. The chronic nature of some cases of gastroparesis, whether from diabetes or other causes, means that any additional factor contributing to its development is a serious consideration.

The GLP-1 Connection to Gastroparesis

The link between GLP-1 medications and gastroparesis stems from the drugs' primary mechanism of action: slowing down the digestive tract. While this effect is beneficial for weight loss by promoting a feeling of fullness, it can become problematic if the slowing is too severe or prolonged. Dr. Periyalwar stated that this side effect comes from "the way GLP-1s affect the digestive tract. The same sense of fullness, or 'early satiety,' that prevents overeating can also slow the gut down" [https://www.nationaljewish.org/specialties/gastroenterology/what-patients-should-know-about-glp-1s-and-gastroparesis]. This slowing, when it becomes extreme, can manifest as gastroparesis. As prescriptions for GLP-1s like Ozempic and Wegovy have increased, so have questions and reports about this specific side effect. Dr. Periyalwar has personally observed an increase in gastroparesis cases directly resulting from GLP-1 usage. For more details, see What Patients Should Know About GLP-1s and Gastroparesis.

Statistical Evidence of Increased Risk

The cohort study comparing GLP-1 agonists to bupropion-naltrexone for weight loss found a statistically significant increase in the risk of gastroparesis. In the primary analysis, GLP-1 agonists had an adjusted hazard ratio (HR) of 3.67 (95% CI, 1.15-11.90) for gastroparesis when compared to bupropion-naltrexone users [https://jamanetwork.com/journals/jama/fullarticle/2810542]. This indicates that users of GLP-1 medications were nearly four times more likely to experience gastroparesis. Looking at the specific incidence rates, among semaglutide users, 9.1 (4 cases) of gastroparesis were found. For liraglutide users, 7.3 (66 cases) were observed. In contrast, bupropion-naltrexone users had an incidence of 3.1 (3 cases). These figures underscore the elevated risk associated with GLP-1s. The E-value for the adjusted HR for gastroparesis was 6.80, suggesting a robust association.

Provider Vigilance and Patient Education

Given the rising incidence of gastroparesis linked to GLP-1 use, provider vigilance and patient education are key for management [https://consultqd.clevelandclinic.org/increased-risk-of-gastroparesis-associated-with-glp-1ra-use-in-type-2-diabetes-patients]. Patients taking GLP-1s should be thoroughly informed about the symptoms of gastroparesis and encouraged to report any persistent or severe digestive issues to their healthcare provider. Early detection and management are crucial to prevent more serious complications. The study "Increased Gastroparesis Risk Tied to GLP-1RA Use in T2DM" also highlighted this need for awareness among both clinicians and patients. While GLP-1s offer significant benefits, the potential for gastroparesis is a serious consideration that demands careful monitoring and proactive communication.

Are There Other Gastrointestinal Risks?

Yes, beyond pancreatitis and gastroparesis, other serious gastrointestinal issues have been linked to GLP-1 agonists. These include biliary disease and bowel obstruction, further highlighting the widespread impact these medications can have on the digestive system. The same large-scale study that identified the pancreatitis and gastroparesis risks also detailed these additional concerns.

Biliary Disease Risk

Biliary disease refers to conditions affecting the gallbladder and bile ducts, which are crucial for digestion, particularly fat breakdown. The cohort study found an increased risk of biliary disease among GLP-1 agonist users. In the primary analysis, GLP-1 agonists had an adjusted hazard ratio (HR) of 1.50 (95% CI, 0.89-2.53) for biliary disease compared to bupropion-naltrexone users [https://jamanetwork.com/journals/jama/fullarticle/2810542]. While the confidence interval here crosses 1, indicating it did not reach statistical significance in the primary adjusted analysis, the crude HR was 1.48 (0.88-2.47), and the numerical incidence was higher. Specifically, among semaglutide users, 11.7 (5 cases) of biliary disease were observed. For liraglutide users, the incidence was 18.6 (162 cases). In contrast, bupropion-naltrexone users had an incidence of 12.6 (16 cases) of biliary disease. The E-value for the adjusted HR for biliary disease was 2.36, which suggests the possibility of unmeasured confounding could explain some of the observed association. However, the higher number of cases in GLP-1 users warrants continued observation and caution.

Bowel Obstruction Risk

Bowel obstruction is a serious condition where a blockage prevents food or liquid from passing through the small or large intestine. This can lead to severe pain, vomiting, abdominal distension, and constipation, and it often requires emergency medical intervention. The study revealed a statistically significant increased risk of bowel obstruction with GLP-1 agonists. The adjusted HR for bowel obstruction was 4.22 (95% CI, 1.02-17.40) compared to bupropion-naltrexone users [https://jamanetwork.com/journals/jama/fullarticle/2810542]. This means GLP-1 users were more than four times as likely to experience a bowel obstruction. Looking at the specific incidence, semaglutide users had 0 cases of bowel obstruction. However, liraglutide users had an incidence of 8.1 (73 cases) of bowel obstruction. Bupropion-naltrexone users had 1.7 (2 cases) of bowel obstruction. The E-value for the adjusted HR for bowel obstruction was 7.91, indicating a strong association. This is a particularly concerning side effect due to its severity and potential for requiring surgery.

Accounting for Patient Characteristics

The researchers carefully considered various patient characteristics to ensure the validity of their findings. They adjusted for factors such as age, sex, and US region. For instance, the mean age for semaglutide users was 53.5 years, for liraglutide users was 51.3 years, and for bupropion-naltrexone users was 45.2 years. In terms of sex, females comprised 44.2% of semaglutide users, 39.0% of liraglutide users, and 17.6% of bupropion-naltrexone users. They also accounted for covariates like alcohol use (2.9% for semaglutide, 0.4% for liraglutide, 0.6% for bupropion-naltrexone), smoking (8.7% for semaglutide, 12.5% for liraglutide, 9.9% for bupropion-naltrexone), and hyperlipidemia (55.6% for semaglutide, 22.8% for liraglutide, 11.5% for bupropion-naltrexone). The study also considered prior abdominal surgery, though its incidence was very low (0% for semaglutide, 0.12% for liraglutide, 0% for bupropion-naltrexone). By controlling for these factors, the study aimed to isolate the effect of the medications themselves on the observed gastrointestinal risks. The consistency of these findings across different analyses reinforces the conclusion that GLP-1 agonists are associated with a range of significant gastrointestinal adverse events, not just pancreatitis and gastroparesis.

Who Was Included in the Research?

The research we analyzed to understand the risks of GLP-1 medications was a large-scale cohort study. It carefully selected participants from a vast healthcare database to ensure the findings were relevant and representative of real-world use. Understanding who was included helps us interpret the results accurately.

The Data Source and Patient Selection

The study utilized a random sample of 16 million patients from the PharMetrics Plus for Academics database, covering the years 2006 to 2020 [https://jamanetwork.com/journals/jama/fullarticle/2810542]. This database is highly comprehensive, capturing 93% of all outpatient prescriptions and physician diagnoses in the US through International Classification of Diseases, Ninth Revision (ICD-9) or ICD-10 codes. This extensive scope allows for a broad and detailed look at healthcare utilization and outcomes across a diverse population. For the cohort study, researchers included new users of semaglutide or liraglutide, the two primary GLP-1 agonists. These were compared against an active comparator group of new users of bupropion-naltrexone, another medication prescribed for weight loss but with a different mechanism of action, making it a suitable control. The selection of "new users" is important because it helps to reduce bias that could arise from long-term users who might have different baseline characteristics or have already experienced side effects. For more details, see GLP-1 drugs: New warning after rise in reported deaths from pancreatitis.

Focus on Weight Loss Indications

A crucial aspect of the study's design was its focus on weight loss. Because semaglutide was marketed for weight loss after the main study period (2021), the researchers ensured that all GLP-1 agonist and bupropion-naltrexone users included in the analysis had an obesity code in their medical records. This code had to appear either within 90 days prior to starting the medication or up to 30 days after cohort entry. This strict criterion ensured that the study population genuinely reflected individuals using these medications for obesity. Furthermore, to isolate the effects related to weight loss rather than diabetes management, patients with a diabetes diagnosis or those prescribed an antidiabetic drug code were specifically excluded from the cohort. This allowed the study to assess the risks of GLP-1s in a population similar to those now receiving them primarily for weight management.

Demographics of the Study Population

The study provided detailed demographic characteristics for each group. For semaglutide users, the mean age was 53.5 years (SD 11.9), while liraglutide users had a mean age of 51.3 years (SD 12.2). The bupropion-naltrexone group was slightly younger, with a mean age of 45.2 years (SD 11.1). In terms of sex, females comprised 44.2% of semaglutide users, 39.0% of liraglutide users, and 17.6% of bupropion-naltrexone users. This shows a varied distribution across the groups, which was accounted for in the statistical adjustments. The cohort also included patients from various US regions, with semaglutide and bupropion-naltrexone users having similar regional distributions (e.g., 34.6% in the Southeast for both), while liraglutide users showed some differences (e.g., 26.1% in the Southeast).

Pre-existing Conditions and Lifestyle Factors

The researchers also collected data on several pre-existing conditions and lifestyle factors that could influence gastrointestinal health. For instance, alcohol use was reported in 2.9% of semaglutide users, 0.4% of liraglutide users, and 0.6% of bupropion-naltrexone users. Smoking was present in 8.7% of semaglutide users, 12.5% of liraglutide users, and 9.9% of bupropion-naltrexone users. Hyperlipidemia, a condition of high cholesterol or fats in the blood, was notably higher among semaglutide users at 55.6%, compared to 22.8% for liraglutide users and 11.5% for bupropion-naltrexone users. Prior abdominal surgery was rare across all groups, at 0% for semaglutide, 0.12% for liraglutide, and 0% for bupropion-naltrexone. These covariates were accounted for in the adjusted analyses to provide a clearer picture of the medications' independent effects. The detailed characterization of the study population enhances the credibility of the findings regarding the gastrointestinal risks associated with GLP-1 agonists.

Frequently Asked Questions

What is the main risk of pancreatitis with GLP-1 medications?

The main risk of pancreatitis with GLP-1 medications is a significantly increased likelihood of developing this serious inflammation. A study found that GLP-1 agonists were associated with an adjusted hazard ratio of 9.09 (95% CI, 1.25-66.00) for pancreatitis compared to bupropion-naltrexone users [https://jamanetwork.com/journals/jama/fullarticle/2810542]. This means GLP-1 users were over nine times more likely to experience pancreatitis. Symptoms include severe abdominal pain, nausea, and vomiting, and immediate medical attention is necessary.

How common is gastroparesis with GLP-1s like Ozempic?

Gastroparesis, or stomach paralysis, is a notable side effect of GLP-1s. The same study reported an adjusted hazard ratio of 3.67 (95% CI, 1.15-11.90) for gastroparesis among GLP-1 agonist users compared to bupropion-naltrexone users [https://jamanetwork.com/journals/jama/fullarticle/2810542]. This indicates that patients on GLP-1s are nearly four times more likely to develop this condition. Among semaglutide users, 9.1 (4) cases of gastroparesis were found, while liraglutide users had 7.3 (66) cases.

Are there other serious side effects to watch out for with GLP-1s?

Yes, beyond pancreatitis and gastroparesis, GLP-1 medications have been linked to other serious gastrointestinal side effects. These include biliary disease, with an adjusted hazard ratio of 1.50 (95% CI, 0.89-2.53), and bowel obstruction, with an adjusted hazard ratio of 4.22 (95% CI, 1.02-17.40) compared to bupropion-naltrexone users [https://jamanetwork.com/journals/jama/fullarticle/2810542]. Bowel obstruction is particularly severe and may require emergency intervention.

Who is most at risk for these gastrointestinal issues?

While the research adjusted for various patient characteristics, the study focused on new users of GLP-1 agonists for weight loss who had an obesity code. The cohort included a diverse group with a mean age of 53.5 years for semaglutide users and 51.3 years for liraglutide users, and varying proportions of males and females [https://jamanetwork.com/journals/jama/fullarticle/2810542]. Patients with a history of diabetes were excluded from this specific analysis, so this risk applies to those using GLP-1s primarily for weight management.

What should I do if I experience severe stomach pain while taking a GLP-1 medication?

If you experience severe stomach pain, especially if it radiates to your back, is accompanied by nausea, vomiting, or fever, you should seek immediate medical attention. These could be symptoms of pancreatitis or another serious gastrointestinal complication like bowel obstruction. It is crucial to inform your healthcare provider about all your medications, including any GLP-1 agonists you are taking.